<?xml version="1.0" encoding="UTF-8"?><xml><records><record><source-app name="Biblio" version="7.x">Drupal-Biblio</source-app><ref-type>17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Angela MC Rose</style></author><author><style face="normal" font="default" size="100%">Nathalie Nicolay</style></author><author><style face="normal" font="default" size="100%">Virginia Sandonis Martín</style></author><author><style face="normal" font="default" size="100%">Clara Mazagatos</style></author><author><style face="normal" font="default" size="100%">Petrović, Goranka</style></author><author><style face="normal" font="default" size="100%">Annabel F Niessen</style></author><author><style face="normal" font="default" size="100%">Ausenda Machado</style></author><author><style face="normal" font="default" size="100%">Odile Launay</style></author><author><style face="normal" font="default" size="100%">Sarah Denayer</style></author><author><style face="normal" font="default" size="100%">Lucie Seyler</style></author><author><style face="normal" font="default" size="100%">Joaquin Baruch</style></author><author><style face="normal" font="default" size="100%">Cristina Burgui</style></author><author><style face="normal" font="default" size="100%">Isabela I Loghin</style></author><author><style face="normal" font="default" size="100%">Domegan, Lisa</style></author><author><style face="normal" font="default" size="100%">Roberta Vaikutyte</style></author><author><style face="normal" font="default" size="100%">Petr Husa</style></author><author><style face="normal" font="default" size="100%">George Panagiotakopoulos</style></author><author><style face="normal" font="default" size="100%">Nassera Aouali</style></author><author><style face="normal" font="default" size="100%">Ralf Dürrwald</style></author><author><style face="normal" font="default" size="100%">Jennifer Howard</style></author><author><style face="normal" font="default" size="100%">Francisco Pozo</style></author><author><style face="normal" font="default" size="100%">Sastre-Palou, Bartolomé</style></author><author><style face="normal" font="default" size="100%">Diana Nonković</style></author><author><style face="normal" font="default" size="100%">Mirjam J Knol</style></author><author><style face="normal" font="default" size="100%">Irina Kislaya</style></author><author><style face="normal" font="default" size="100%">Liem binh Luong Nguyen</style></author><author><style face="normal" font="default" size="100%">Nathalie Bossuyt</style></author><author><style face="normal" font="default" size="100%">Thomas Demuyser</style></author><author><style face="normal" font="default" size="100%">Aušra Džiugytė</style></author><author><style face="normal" font="default" size="100%">Iván Martínez-Baz</style></author><author><style face="normal" font="default" size="100%">Corneliu Popescu</style></author><author><style face="normal" font="default" size="100%">Róisín Duffy</style></author><author><style face="normal" font="default" size="100%">Monika Kuliešė</style></author><author><style face="normal" font="default" size="100%">Lenka Součková</style></author><author><style face="normal" font="default" size="100%">Stella Michelaki</style></author><author><style face="normal" font="default" size="100%">Marc Simon</style></author><author><style face="normal" font="default" size="100%">Janine Reiche</style></author><author><style face="normal" font="default" size="100%">María Teresa Otero-Barrós</style></author><author><style face="normal" font="default" size="100%">Zvjezdana Lovrić Makarić</style></author><author><style face="normal" font="default" size="100%">Patricia CJL Bruijning-Verhagen</style></author><author><style face="normal" font="default" size="100%">Verónica Gomez</style></author><author><style face="normal" font="default" size="100%">Zineb Lesieur</style></author><author><style face="normal" font="default" size="100%">Cyril Barbezange</style></author><author><style face="normal" font="default" size="100%">Els van Nedervelde</style></author><author><style face="normal" font="default" size="100%">Maria-Louise Borg</style></author><author><style face="normal" font="default" size="100%">Jesús Castilla</style></author><author><style face="normal" font="default" size="100%">Mihaela Lazar</style></author><author><style face="normal" font="default" size="100%">O'Donnell, Joan</style></author><author><style face="normal" font="default" size="100%">Indrė Jonikaite</style></author><author><style face="normal" font="default" size="100%">Regina Demlová</style></author><author><style face="normal" font="default" size="100%">Marina Amerali</style></author><author><style face="normal" font="default" size="100%">Gil Wirtz</style></author><author><style face="normal" font="default" size="100%">Kristin Tolksdorf</style></author><author><style face="normal" font="default" size="100%">Marta Valenciano</style></author><author><style face="normal" font="default" size="100%">Sabrina Bacci</style></author><author><style face="normal" font="default" size="100%">Kissling, Esther</style></author></authors><translated-authors><author><style face="normal" font="default" size="100%">I-MOVE-COVID-19 hospital study team</style></author><author><style face="normal" font="default" size="100%">VEBIS hospital study team</style></author><author><style face="normal" font="default" size="100%">Members of the I-MOVE-COVID-19 and VEBIS hospital study teams (in addition to the named authors)</style></author></translated-authors></contributors><titles><title><style face="normal" font="default" size="100%">Vaccine effectiveness against COVID-19 hospitalisation in adults (≥ 20 years) during Alpha- and Delta-dominant circulation: I-MOVE-COVID-19 and VEBIS SARI VE networks, Europe, 2021.</style></title><secondary-title><style face="normal" font="default" size="100%">Euro Surveill</style></secondary-title></titles><keywords><keyword><style  face="normal" font="default" size="100%">Adult</style></keyword><keyword><style  face="normal" font="default" size="100%">BNT162 Vaccine</style></keyword><keyword><style  face="normal" font="default" size="100%">COVID-19</style></keyword><keyword><style  face="normal" font="default" size="100%">Europe</style></keyword><keyword><style  face="normal" font="default" size="100%">Hospitalization</style></keyword><keyword><style  face="normal" font="default" size="100%">Humans</style></keyword><keyword><style  face="normal" font="default" size="100%">RNA, Viral</style></keyword><keyword><style  face="normal" font="default" size="100%">SARS-CoV-2</style></keyword><keyword><style  face="normal" font="default" size="100%">Vaccine Efficacy</style></keyword></keywords><dates><year><style  face="normal" font="default" size="100%">2023</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2023 Nov</style></date></pub-dates></dates><volume><style face="normal" font="default" size="100%">28</style></volume><language><style face="normal" font="default" size="100%">eng</style></language><abstract><style face="normal" font="default" size="100%">&lt;p&gt;IntroductionTwo large multicentre European hospital networks have estimated vaccine effectiveness (VE) against COVID-19 since 2021.AimWe aimed to measure VE against PCR-confirmed SARS-CoV-2 in hospitalised severe acute respiratory illness (SARI) patients ≥ 20 years, combining data from these networks during Alpha (March-June)- and Delta (June-December)-dominant periods, 2021.MethodsForty-six participating hospitals across 14 countries follow a similar generic protocol using the test-negative case-control design. We defined complete primary series vaccination (PSV) as two doses of a two-dose or one of a single-dose vaccine ≥ 14 days before onset.ResultsWe included 1,087 cases (538 controls) and 1,669 cases (1,442 controls) in the Alpha- and Delta-dominant periods, respectively. During the Alpha period, VE against hospitalisation with SARS-CoV2 for complete Comirnaty PSV was 85% (95% CI: 69-92) overall and 75% (95% CI: 42-90) in those aged ≥ 80 years. During the Delta period, among SARI patients ≥ 20 years with symptom onset ≥ 150 days from last PSV dose, VE for complete Comirnaty PSV was 54% (95% CI: 18-74). Among those receiving Comirnaty PSV and mRNA booster (any product) ≥ 150 days after last PSV dose, VE was 91% (95% CI: 57-98). In time-since-vaccination analysis, complete all-product PSV VE was &amp;gt; 90% in those with their last dose &amp;lt; 90 days before onset; ≥ 70% in those 90-179 days before onset.ConclusionsOur results from this EU multi-country hospital setting showed that VE for complete PSV alone was higher in the Alpha- than the Delta-dominant period, and addition of a first booster dose during the latter period increased VE to over 90%.&lt;/p&gt;
</style></abstract><issue><style face="normal" font="default" size="100%">47</style></issue></record></records></xml>